Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Idhifa (enasidenib)
Pharma
Rigel's nod for Rezlidhia sets up battle with Servier in AML
Rigel has won approval for Rezlidhia for adults with relapsed or refractory acute myeloid leukemia with the IDH1 genetic mutation.
Kevin Dunleavy
Dec 2, 2022 9:57am
The top 20 most expensive pharmacy drugs in the U.S. in 2021
Mar 9, 2021 12:12pm
Bristol Myers' aging Vidaza goes oral with FDA nod in AML
Sep 2, 2020 9:40am
BMS' targeted AML drug Idhifa fails to extend patients' lives
Aug 25, 2020 11:49am
Agios crowns Jackie Fouse CEO to spearhead leukemia rollouts
Sep 5, 2018 12:10pm
Agios wins FDA nod for targeted AML drug Tibsovo
Jul 23, 2018 12:00pm
